Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer (MPV-CICU)
研究概览
详细说明
This retrospective, observational, single-center study will evaluate the predictive value of initial Mean Platelet Volume (MPV) and other hemogram parameters (such as Red Cell Distribution Width [RDW] and platelet count) on intensive care and hospital mortality. The primary objective is to investigate the correlation between these routinely measured, cost-effective biomarkers and survival outcomes in oncological critical care patients. The study hypotheses are structured as follows:
- H0: There is no significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer.
- H1: There is a significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer. Data regarding demographics (age, sex), clinical diagnoses, comorbidities, length of stay, APACHE II, SOFA scores, and laboratory parameters (CRP, procalcitonin) will be extracted from hospital electronic database records. All patient data will be anonymized before statistical analysis.
Note on Study Design: This study is designed as a retrospective cohort study. Due to system registry constraints in the protocol module, the time perspective has been specified as 'Other' (Retrospective Cohort).
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Ankara、土耳其(türkiye)
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adult patients aged 18 years and older.
- Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
- Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
- Patients with an ICU length of stay longer than 24 hours.
- Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.
Exclusion Criteria:
- Patients under the age of 18.
- Patients who stayed in the intensive care unit for less than 24 hours.
- Patients with missing or incomplete medical charts, laboratory data, or survival status records.
- Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
- Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Oncological ICU Patients
Adult patients (aged 18 and older) with a confirmed cancer diagnosis who were admitted to the anesthesia intensive care unit for longer than 24 hours between the years 2020 and 2025
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Intensive Care Unit (ICU) Mortality
大体时间:From the date of ICU admission up to ICU discharge, assessed up to 30 days.
|
The percentage of oncological patients who died during their stay in the anesthesia intensive care unit.
This will be calculated based on the electronic health records and patient files.
|
From the date of ICU admission up to ICU discharge, assessed up to 30 days.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hospital Mortality
大体时间:From the date of hospital admission up to hospital discharge, assessed up to 60 days.
|
The percentage of oncological patients who died during their overall hospital stay (including post-ICU ward follow-up).
|
From the date of hospital admission up to hospital discharge, assessed up to 60 days.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2026-05/106
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.